Patents Assigned to California Pacific Medical Center
-
Publication number: 20080092909Abstract: A medical face mask comprising a central transparent portion, an outer filter portion and, optionally, one or more antimicrobial agents is described.Type: ApplicationFiled: September 20, 2005Publication date: April 24, 2008Applicant: California Pacific Medical CenterInventor: Jeanne Hahne
-
Patent number: 7342114Abstract: 4-O esters of podophyllotoxin and 4?-demethylepipodophyllotoxin are provided. The compounds are 4-O esters of an alkanoic acid or substituted alkanoic acid and podophyllotoxin and 4?-demethylepipodophyllotoxin. The compounds are useful for treating cancer.Type: GrantFiled: July 1, 2003Date of Patent: March 11, 2008Assignees: California Pacific Medical Center, Catholic Healthcare West, DBA St. Mary's Medical CenterInventor: Li-Xi Yang
-
Patent number: 7056663Abstract: Methods of determining the likelihood of the re-occurrence of tumors and of determining the aggressiveness of post-surgical treatment are provided which rely on analysis of a loss of heterogeneity at the particular chromosomal locus 3p24.3. Loss of expression or hypermethylation of the thyroid hormone receptor ?1 gene is also predictive of an increased re-occurrence of tumors.Type: GrantFiled: March 23, 2001Date of Patent: June 6, 2006Assignee: California Pacific Medical CenterInventors: Shanaz H. Dairkee, Zheng Li
-
Patent number: 6933302Abstract: (20) esters of camptothecin analogs are provided. The compounds are (20) esters of an aminoalkanoic acid or an imidoalkanoic acid and homocamptothecin, which is optionally substituted at the 7, 9, 10, 11, and 12 positions of the homocamptothecin ring. The compounds are useful for treating cancer.Type: GrantFiled: June 3, 2003Date of Patent: August 23, 2005Assignees: California Pacific Medical Center, Catholic Healthcare WestInventor: Li-Xi Yang
-
Patent number: 6855720Abstract: (20S) esters of camptothecin analogs are provided. The compounds are (20S) esters of an aminoalkanoic acid or an imidoalkanoic acid and camptothecin, which is optionally substituted at the 7, 9, 10, 11, and 12 positions of the camptothecin ring. The compounds are useful for treating cancer.Type: GrantFiled: June 14, 2002Date of Patent: February 15, 2005Assignees: California Pacific Medical Center, Catholic Healthcare WestInventor: Li-Xi Yang
-
Publication number: 20050014165Abstract: A panel of biomarkers has been identified for analysis of colorectal cancer. The panel, originally identified using a mouse colon cancer model, has been used to assess changes in human tissue from surgical and biopsy samples against a normal human control panel of biomarkers. The panel may be used for providing a cost effective, rapid, noninvasive procedure for risk assessment, early diagnosis, establishing prognosis, monitoring patient treatment, detecting relapse, and for the discovery of therapeutic intervention of colorectal cancer.Type: ApplicationFiled: October 22, 2003Publication date: January 20, 2005Applicant: California Pacific Medical CenterInventors: Nancy Lee, Ling Chen
-
Patent number: 6825207Abstract: (20S) esters of camptothecin analogs are provided. The compounds are (20S) esters of an aminoalkanoic acid or an imidoalkanoic acid and camptothecin, which is optionally substituted at the 7, 9, 10, 11, and 12 positions of the camptothecin ring. The compounds are useful for treating cancer.Type: GrantFiled: May 23, 2002Date of Patent: November 30, 2004Assignees: California Pacific Medical Center, Catholic Healthcare WestInventors: Li-Xi Yang, Xiandao Pan, Huijuan Wang
-
Patent number: 6825236Abstract: Certain N-deacetylcolchicine and N-deacetylthiocolchine derivatives are described wherein the 7-N position on the B ring is substituted with the group —C(O)—(CHR4)m—AR, wherein m is an integer of 0-10, A is S, O, N or a covalent bond; R1 is substituted phenyl or substituted benzoyl; optionally substituted cycloalkyl of 3-7 carbons; optionally substituted naphtyl; an optionally substituted imide ring; an optionally substituted 5 or 6 member heterocycle with at least one N, S, or O in the ring; or an optionally substituted fused heterocyclic or fused carboxyclic ring system; R2 (at the 2-position of the A ring) is methoxy, hydroxy, or methylenedioxy when taken together with R3; R3 (at the 3-position of the A ring) is methoxy, hydroxy, a monosaccharide radical, or is methylenedioxy when taken together with R2; and R4 is H or is H or methyl when m is 1. Also dimers of such compounds are disclosed.Type: GrantFiled: April 14, 2003Date of Patent: November 30, 2004Assignees: California Pacific Medical Center, Catholic Healthcare WestInventor: Li-Xi Yang
-
Patent number: 6686146Abstract: The present invention encompasses methods for determining the likelihood that benign hyperplastic breast tissue or normal breast tissue adjacent to carcinoma tissue will become malignant. The methods comprise substantially isolating the tissue; and determining loss of heterozygosity (LOH) at chromosome 3p24 in the tissue. LOH at chromosome 3p24 is a prognostic indicator that the tissue may become malignant.Type: GrantFiled: October 18, 1996Date of Patent: February 3, 2004Assignee: California Pacific Medical CenterInventors: Guoren Deng, You Lu, Helene S. Smith
-
Patent number: 6423707Abstract: Novel nitroimidazole compounds are provided that have a substituent linked via an ester linkage. The ester linkage may be obtained by derivation of the hydroxyl group of metronidazole. These nitroimidazole ester analogs have anti-microbial activity, with a number of novel compounds having an anti-microbial activity that is significantly improved with respect to metronidazole.Type: GrantFiled: August 28, 2000Date of Patent: July 23, 2002Assignee: California Pacific Medical CenterInventors: Li-Xi Yang, Hui-Juan Wang, Xiandao Pan
-
Patent number: 6403604Abstract: (20S) esters of camptothecin analogs are provided. The compounds are (20S) esters of an aminoalkanoic acid or an imidoalkanoic acid and camptothecin, which is optionally substituted at the 7, 9, 10, 11, and 12 positions of the camptothecin ring. The compounds are useful for treating cancer.Type: GrantFiled: March 1, 2001Date of Patent: June 11, 2002Assignee: California Pacific Medical CenterInventors: Li-Xi Yang, Xiandao Pan, Huijuan Wang
-
Patent number: 6350756Abstract: (20S) esters of camptothecin analogs are provided. The compounds are (20S) esters of an oxyalkanoic acid and camptothecin, which is optionally substituted at the 7, 9, 10, 11, and 12 positions of the camptothecin ring. The compounds are useful for treating cancer.Type: GrantFiled: March 1, 2001Date of Patent: February 26, 2002Assignee: California Pacific Medical CenterInventors: Li-Xi Yang, Xiandao Pan, Huijuan Wang
-
Patent number: 5776683Abstract: New methods are disclosed for detecting cancer associated genes, and obtaining corresponding cDNA fragments. The methods involve supplying RNA preparations from control cells, and from a plurality of different cancer cells that share a duplicated or deleted gene in the same region of a chromosome. Amplified cDNA copies are displayed, and then selected based on differences in abundance of RNA between preparations. Optional additional screening steps involve surveying panels of cancer cells using the cDNA for RNA overabundance with or without gene duplication. By applying these methods, cDNA sequences derived from four novel genes associated with breast cancer were obtained and characterized. Each of the genes was duplicated in about 60% of the cancer cell lines tested; while other cells showed RNA overabundance without gene duplication. Genes with these properties are particularly useful in cancer diagnosis and treatment.Type: GrantFiled: July 11, 1996Date of Patent: July 7, 1998Assignee: California Pacific Medical CenterInventors: Helene S. Smith, Ling-Chun Chen
-
Patent number: 5759776Abstract: cDNA sequences derived from four novel genes associated with breast cancer are provided. In over about 60% of the cancer cell lines tested, RNA hybridizing with the cDNAs were substantially more abundant than in normal cells. Most of the cell lines also showed a duplication of the corresponding gene, which probably contributed to the increased level of RNA in the cell. However, for each of the four genes, there were some cell lines which had RNA overabundance without gene duplication. This suggests that the gene product is sufficiently important to the cancer process that cells will use several alternative mechanisms to achieve increased expression. The polynucleotides, polypeptides, and antibodies provided by this invention are expected to be particularly useful in diagnosis and treatment of breast cancer. Also provided is a general method for obtaining cDNA with similar properties that may be associated with breast cancer and other malignancies.Type: GrantFiled: June 5, 1995Date of Patent: June 2, 1998Assignee: California Pacific Medical CenterInventors: Helene Smith, Ling-Chun Chen
-
Patent number: 5747027Abstract: The invention features a purified hyaluronidase BH55 polypeptide isolated from a mammalian species, preferably bovine or human. The invention also features DNA encoding BH55, vectors and transformed host cells containing DNA encoding BH55, the methods of making BH55 hyaluronidase polypeptides, and the antibodies that specifically bind BH55.Type: GrantFiled: April 7, 1995Date of Patent: May 5, 1998Assignees: The Regents of the University of California, Sansum Medical Research Foundation, California Pacific Medical Center, Research InstituteInventors: Robert Stern, Gregory I. Frost, Jackson Hall, Svetlana Shuster, Bent Formby, Gail T. Colbern
-
Patent number: RE39707Abstract: (20S) esters of camptothecin analogs are provided. The compounds are (20S) esters of an oxyalkanoic acid and camptothecin, which is are optionally substituted at the 7, 9, 10, 11, and 12 positions of the camptothecin ring. The compounds are useful for treating cancer.Type: GrantFiled: January 16, 2003Date of Patent: June 26, 2007Assignees: Catholic Healthcare West, California Pacific Medical CenterInventors: Li-Xi Yang, Xiando Pan, Huijan Wang